Mia Schmidt-Hansen
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mia Schmidt-Hansen has a total of 18 co-authors. Here are the top co-authors by number of shared publications:
Elise Hasler
National Guideline Alliance Royal College of Obstetricians and Gynaecologists London UK
6 shared publicationsSharon Cameron
Sexual and Reproductive Health services NHS Lothian Edinburgh Scotland
6 shared publications- Jonathan Lord
Medical Director, MSI Reproductive Choices, London, UK
3 shared publications Anuja Pandey
Amaris Consulting Work Life ‐ Camden London UK
2 shared publicationsPatricia A. Lohr
British Pregnancy Advisory Service Stratford Upon Avon UK
2 shared publications- Patricia A. Lohr
Centre for Reproductive Research & Communication, British Pregnancy Advisory Service (BPAS), London, UK
2 shared publications
Latest Publications
- 16 October 2020
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 100 (4) , 727-735
Expulsion at home for early medical abortion: A systematic review with meta‐analyses
Introduction: The safety and acceptability of medical abortion using mifepristone and misoprostol at home at ≤9+0 weeks’ gestation is well established. However, the upper gestational limit at which the procedure remains safe and acceptable at home is not known. To inform a national guideline on abortion care we conducted a systematic review to determine what gestational limit for expulsion at home offers the best balance of benefits and harms for women who are having medical abortion.Material and methods: We searched Embase, MEDLINE, Cochrane Library, Cinahl Plus and Web‐of‐Science on 2 January 2020 for prospective and retrospective cohort studies with ≥50 women per gestational age group, published in English from 1995 onwards, that included women undergoing medical abortion and compared home expulsion of pregnancies of ≤9+0 weeks’ gestational age with pregnancies of 9+1‐10+0 weeks or >10+1 weeks’ gestational age, or compared the latter two gestational age groups. We assessed risk‐of‐bias using the Newcastle‐Ottowa scale. All outcomes were meta‐analyzed as risk ratios (RR) using the Mantel‐Haenszel method. The certainty of the evidence was assessed using GRADE.Results: Six studies (n = 3381) were included. The “need for emergency care/admission to hospital” (RR = 0.79, 95% confidence interval [CI] 0.45‐1.4), “hemorrhage requiring transfusion/≥500 mL blood loss” (RR = 0.62, 95% CI 0.11‐3.55), patient satisfaction (RR = 0.99, 95% CI 0.95‐1.03), pain (RR = 0.91, 95% CI 0.82‐1.02), and “complete abortion without the need for surgical intervention” (RR = 1.03, 95% CI 1‐1.05) did not differ statistically significantly between the ≤9+0 and >9+0 weeks’ gestation groups. The rates of vomiting (RR = 0.8, 95% CI 0.69‐0.93) and diarrhea (RR = 0.85, 95% CI 0.73‐0.99) were statistically significantly lower in the ≤9+0 weeks group but these differences were not considered clinically important. We found no studies comparing pregnancies of 9+1‐10+0 weeks’ gestation with pregnancies of >10+0 weeks’ gestation. The certainty of this evidence was predominantly low and mainly compromised by low event rates and loss to follow up.Conclusions: Women who are having a medical abortion and will be taking mifepristone up to and including 10+0 weeks’ gestation should be offered the option of expulsion at home after they have taken the misoprostol. Further research needs to determine whether the gestational limit for home expulsion can be extended beyond 10+0 weeks.
- 16 October 2020
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 100 (4) , 727-735
Expulsion at home for early medical abortion: A systematic review with meta‐analyses
Introduction: The safety and acceptability of medical abortion using mifepristone and misoprostol at home at ≤9+0 weeks’ gestation is well established. However, the upper gestational limit at which the procedure remains safe and acceptable at home is not known. To inform a national guideline on abortion care we conducted a systematic review to determine what gestational limit for expulsion at home offers the best balance of benefits and harms for women who are having medical abortion.Material and methods: We searched Embase, MEDLINE, Cochrane Library, Cinahl Plus and Web‐of‐Science on 2 January 2020 for prospective and retrospective cohort studies with ≥50 women per gestational age group, published in English from 1995 onwards, that included women undergoing medical abortion and compared home expulsion of pregnancies of ≤9+0 weeks’ gestational age with pregnancies of 9+1‐10+0 weeks or >10+1 weeks’ gestational age, or compared the latter two gestational age groups. We assessed risk‐of‐bias using the Newcastle‐Ottowa scale. All outcomes were meta‐analyzed as risk ratios (RR) using the Mantel‐Haenszel method. The certainty of the evidence was assessed using GRADE.Results: Six studies (n = 3381) were included. The “need for emergency care/admission to hospital” (RR = 0.79, 95% confidence interval [CI] 0.45‐1.4), “hemorrhage requiring transfusion/≥500 mL blood loss” (RR = 0.62, 95% CI 0.11‐3.55), patient satisfaction (RR = 0.99, 95% CI 0.95‐1.03), pain (RR = 0.91, 95% CI 0.82‐1.02), and “complete abortion without the need for surgical intervention” (RR = 1.03, 95% CI 1‐1.05) did not differ statistically significantly between the ≤9+0 and >9+0 weeks’ gestation groups. The rates of vomiting (RR = 0.8, 95% CI 0.69‐0.93) and diarrhea (RR = 0.85, 95% CI 0.73‐0.99) were statistically significantly lower in the ≤9+0 weeks group but these differences were not considered clinically important. We found no studies comparing pregnancies of 9+1‐10+0 weeks’ gestation with pregnancies of >10+0 weeks’ gestation. The certainty of this evidence was predominantly low and mainly compromised by low event rates and loss to follow up.Conclusions: Women who are having a medical abortion and will be taking mifepristone up to and including 10+0 weeks’ gestation should be offered the option of expulsion at home after they have taken the misoprostol. Further research needs to determine whether the gestational limit for home expulsion can be extended beyond 10+0 weeks.
- 1 June 2020
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 222 (6) , 551-563.e13
Follow-up strategies to confirm the success of medical abortion of pregnancies up to 10 weeks’ gestation: a systematic review with meta-analyses
- 1 June 2020
- Published by Elsevier in American Journal of Obstetrics and Gynecology
- Vol. 222 (6) , 551-563.e13
Follow-up strategies to confirm the success of medical abortion of pregnancies up to 10 weeks’ gestation: a systematic review with meta-analyses
- 17 March 2020
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 47 (3) , e10
Surgical or medical abortion of pregnancies between 13+0 and 23+6 weeks’ gestation? A systematic review and new NICE national guidelines
Background: Abortion in the second trimester may be performed surgically or medically. The objective of this systematic review was to examine the effectiveness, safety and acceptability/satisfaction of surgical compared with medical abortion of pregnancy between 13+0 and 23+6 weeks’ gestation for a new national guideline. Methods: We searched Embase, Medline and the Cochrane Library on 4 March 2019. We included randomised controlled trials (RCTs; any size) and non-randomised comparative studies with n≥100 in each arm, published in English from 1985. Risk-of-bias was assessed using the Cochrane Collaboration checklist for RCTs. Meta-analysis of risk ratios (RRs) used the Mantel-Haenszel method. The quality of the evidence was assessed using GRADE. Results: Two RCTs (n=140) were included. ‘Incomplete abortion requiring surgical intervention’ was clinically significantly higher with medical than surgical methods (RR=4.58, 95% CI 1.07 to 19.64). ‘Abortion completed by the intended method’ was statistically, but not clinically, significantly lower after medical than surgical methods, but was marked by high between-study heterogeneity (RR=0.88, 95% CI 0.79 to 0.98). To the extent that ‘haemorrhage requiring transfusion/≥500 mL blood loss’, ‘uterine injury’, ‘cervical injury requiring repair’ and ‘infection reported within 1 month of abortion’ were reported, they did not differ significantly between methods. Depending on measurement method, ‘patient satisfaction/acceptability’ was either clinically significantly higher or comparable after surgical than medical methods. The quality of this evidence was limited by low event rates and attrition bias. Conclusion: Based on this evidence and consensus, women should be offered the choice of medical or surgical methods of abortion between 13+0 and 23+6 weeks’ gestation, unless not clinically appropriate.
- 17 March 2020
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 47 (3) , e10
Surgical or medical abortion of pregnancies between 13+0 and 23+6 weeks’ gestation? A systematic review and new NICE national guidelines
Background: Abortion in the second trimester may be performed surgically or medically. The objective of this systematic review was to examine the effectiveness, safety and acceptability/satisfaction of surgical compared with medical abortion of pregnancy between 13+0 and 23+6 weeks’ gestation for a new national guideline. Methods: We searched Embase, Medline and the Cochrane Library on 4 March 2019. We included randomised controlled trials (RCTs; any size) and non-randomised comparative studies with n≥100 in each arm, published in English from 1985. Risk-of-bias was assessed using the Cochrane Collaboration checklist for RCTs. Meta-analysis of risk ratios (RRs) used the Mantel-Haenszel method. The quality of the evidence was assessed using GRADE. Results: Two RCTs (n=140) were included. ‘Incomplete abortion requiring surgical intervention’ was clinically significantly higher with medical than surgical methods (RR=4.58, 95% CI 1.07 to 19.64). ‘Abortion completed by the intended method’ was statistically, but not clinically, significantly lower after medical than surgical methods, but was marked by high between-study heterogeneity (RR=0.88, 95% CI 0.79 to 0.98). To the extent that ‘haemorrhage requiring transfusion/≥500 mL blood loss’, ‘uterine injury’, ‘cervical injury requiring repair’ and ‘infection reported within 1 month of abortion’ were reported, they did not differ significantly between methods. Depending on measurement method, ‘patient satisfaction/acceptability’ was either clinically significantly higher or comparable after surgical than medical methods. The quality of this evidence was limited by low event rates and attrition bias. Conclusion: Based on this evidence and consensus, women should be offered the choice of medical or surgical methods of abortion between 13+0 and 23+6 weeks’ gestation, unless not clinically appropriate.
- Open Access
- 25 February 2020
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 26 (2) , 141-160
Long-acting reversible contraception immediately after medical abortion: systematic review with meta-analyses
BACKGROUND: Long-acting reversible contraceptives (LARCs) are safe, effective and convenient post-abortal methods. However, there is concern that some LARCs may reduce the effectiveness of abortifacient drugs or result in other adverse outcomes. OBJECTIVE AND RATIONALE: We undertook two systematic reviews to examine the early administration of LARCs in women undergoing medical abortion with mifepristone and misoprostol. (i) For women who are having a medical abortion and who plan to use a progestogen-only contraceptive implant or injectable, does administration of the contraception at the same time as mifepristone influence the efficacy of the abortion? (Implant/injectable review). (ii) For women who have had a medical abortion, how soon after expulsion of the products of conception is it safe to insert an intrauterine contraceptive device/system? (LNG-IUS/Cu-IUD review). SEARCH METHODS: On 19 November 2018, we searched Embase Classic, Embase; Ovid MEDLINE(R) including Daily and Epub Ahead-of-Print, In-Process and Other Non-Indexed Citations; the Cochrane Library; Cinahl Plus; and Web of Science Core Collection. Eligible studies were randomised controlled trials (RCTs), in English from 1985 (Implant/injectable review) or 2007 (LNG-IUS/Cu-IUD review) onwards, conducted in women undergoing medical abortion with mifepristone and misoprostol and studying either (i) simultaneous administration of mifepristone and a progestogen-only contraceptive implant or injectable compared to administration >24 h after mifepristone, or (ii) immediate insertion of intrauterine contraception after expulsion of the products of conception compared to early insertion (≤7 days) or to delayed insertion (>7 days) or early compared to delayed insertion. One author assessed the risk of bias in the studies using the Cochrane Collaboration checklist for RCTs. All the outcomes were analysed as risk ratios and meta-analysed in Review Manager 5.3 using the Mantel–Haenszel statistical method and a fixed-effect model. The overall quality of the evidence was assessed using GRADE. OUTCOMES: Two RCTs (n = 1027) showed lower ‘subsequent unintended pregnancy’ rates and higher ‘patient satisfaction’ rates, and no other differences, after simultaneous administration of mifepristone and the implant compared to delayed administration. One RCT (n = 461) showed higher ‘patient satisfaction’ rates after simultaneous administration than after delayed administration of mifepristone and the injectable, but no other differences between these interventions. Three RCTs (n = 536) found no differences other than higher copper IUC uptake after early compared to delayed insertion at ≤9 weeks of gestation and higher rates of IUC expulsion, continuation and uptake after immediate compared to delayed insertion at 9+1–12+0 weeks of gestation and higher IUC continuation rates after immediate compared to delayed insertion at 12+1–20+0 weeks of gestation. The quality of this evidence ranged from very low to high and was mainly compromised by low event rates, high attrition and no blinding. WIDER IMPLICATIONS: The contraceptive implant or injectable should be offered on the day of taking mifepristone. Intrauterine methods of contraception should be offered as soon as possible after expulsion of the pregnancy.
- 25 February 2020
- Published by Oxford University Press (OUP) in Human Reproduction Update
- Vol. 26 (2) , 141-160
Open AccessLong-acting reversible contraception immediately after medical abortion: systematic review with meta-analyses
BACKGROUND: Long-acting reversible contraceptives (LARCs) are safe, effective and convenient post-abortal methods. However, there is concern that some LARCs may reduce the effectiveness of abortifacient drugs or result in other adverse outcomes. OBJECTIVE AND RATIONALE: We undertook two systematic reviews to examine the early administration of LARCs in women undergoing medical abortion with mifepristone and misoprostol. (i) For women who are having a medical abortion and who plan to use a progestogen-only contraceptive implant or injectable, does administration of the contraception at the same time as mifepristone influence the efficacy of the abortion? (Implant/injectable review). (ii) For women who have had a medical abortion, how soon after expulsion of the products of conception is it safe to insert an intrauterine contraceptive device/system? (LNG-IUS/Cu-IUD review). SEARCH METHODS: On 19 November 2018, we searched Embase Classic, Embase; Ovid MEDLINE(R) including Daily and Epub Ahead-of-Print, In-Process and Other Non-Indexed Citations; the Cochrane Library; Cinahl Plus; and Web of Science Core Collection. Eligible studies were randomised controlled trials (RCTs), in English from 1985 (Implant/injectable review) or 2007 (LNG-IUS/Cu-IUD review) onwards, conducted in women undergoing medical abortion with mifepristone and misoprostol and studying either (i) simultaneous administration of mifepristone and a progestogen-only contraceptive implant or injectable compared to administration >24 h after mifepristone, or (ii) immediate insertion of intrauterine contraception after expulsion of the products of conception compared to early insertion (≤7 days) or to delayed insertion (>7 days) or early compared to delayed insertion. One author assessed the risk of bias in the studies using the Cochrane Collaboration checklist for RCTs. All the outcomes were analysed as risk ratios and meta-analysed in Review Manager 5.3 using the Mantel–Haenszel statistical method and a fixed-effect model. The overall quality of the evidence was assessed using GRADE. OUTCOMES: Two RCTs (n = 1027) showed lower ‘subsequent unintended pregnancy’ rates and higher ‘patient satisfaction’ rates, and no other differences, after simultaneous administration of mifepristone and the implant compared to delayed administration. One RCT (n = 461) showed higher ‘patient satisfaction’ rates after simultaneous administration than after delayed administration of mifepristone and the injectable, but no other differences between these interventions. Three RCTs (n = 536) found no differences other than higher copper IUC uptake after early compared to delayed insertion at ≤9 weeks of gestation and higher rates of IUC expulsion, continuation and uptake after immediate compared to delayed insertion at 9+1–12+0 weeks of gestation and higher IUC continuation rates after immediate compared to delayed insertion at 12+1–20+0 weeks of gestation. The quality of this evidence ranged from very low to high and was mainly compromised by low event rates, high attrition and no blinding. WIDER IMPLICATIONS: The contraceptive implant or injectable should be offered on the day of taking mifepristone. Intrauterine methods of contraception should be offered as soon as possible after expulsion of the pregnancy.
- 20 February 2020
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 46 (4) , 270-278
Simultaneous compared to interval administration of mifepristone and misoprostol for medical abortion up to 10+0weeks' gestation: a systematic review with meta-analyses
Background: Medical abortion with mifepristone and misoprostol usually involves an interval of 36–48 hours between administering these drugs; however, it is possible that the clinical efficacy at early gestations may be maintained when the drugs are taken simultaneously. The objective of this systematic review was to determine the safety and effectiveness of simultaneous compared with interval administration of mifepristone and misoprostol for abortion up to 10+0weeks’ gestation.Methods: We searched Embase Classic, Embase; Ovid MEDLINE(R) including Daily, and Epub Ahead-of-Print, In-Process & Other Non-Indexed Citations; and Cochrane Library on 11 December 2019. We included randomised controlled trials (RCTs), published in English from 1985, comparing simultaneous to interval administration of mifepristone and misoprostol for early abortion. Risk of bias was assessed using the Cochrane Collaboration checklist for RCTs. Meta-analysis of risk ratios (RRs) using the Mantel-Haenszel method were performed. The quality of the evidence was assessed using GRADE.Results: Meta-analyses of three RCTs (n=1280) showed no differences in ‘ongoing pregnancy’ (RR 1.78, 95% CI 0.38 to 8.36), ‘haemorrhage requiring transfusion or ≥500 mL blood loss’ (RR 0.11, 95% CI 0.01 to 2.03) and ‘incomplete abortion with the need for surgical intervention’ (RR 1.30, 95% CI 0.76 to 2.25) between the interventions. Individual study results showed no difference in patient satisfaction, or ‘need for repeat misoprostol’, although ‘time to onset of bleeding or cramping’ was longer after simultaneous than interval administration. The quality of evidence was very low to moderate.Conclusion: The published data support the use of simultaneous mifepristone and misoprostol for medical abortion up to 9+0weeks in women who prefer this method of administration.
- 20 February 2020
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 46 (4) , 270-278
Simultaneous compared to interval administration of mifepristone and misoprostol for medical abortion up to 10+0weeks' gestation: a systematic review with meta-analyses
Background: Medical abortion with mifepristone and misoprostol usually involves an interval of 36–48 hours between administering these drugs; however, it is possible that the clinical efficacy at early gestations may be maintained when the drugs are taken simultaneously. The objective of this systematic review was to determine the safety and effectiveness of simultaneous compared with interval administration of mifepristone and misoprostol for abortion up to 10+0weeks’ gestation.Methods: We searched Embase Classic, Embase; Ovid MEDLINE(R) including Daily, and Epub Ahead-of-Print, In-Process & Other Non-Indexed Citations; and Cochrane Library on 11 December 2019. We included randomised controlled trials (RCTs), published in English from 1985, comparing simultaneous to interval administration of mifepristone and misoprostol for early abortion. Risk of bias was assessed using the Cochrane Collaboration checklist for RCTs. Meta-analysis of risk ratios (RRs) using the Mantel-Haenszel method were performed. The quality of the evidence was assessed using GRADE.Results: Meta-analyses of three RCTs (n=1280) showed no differences in ‘ongoing pregnancy’ (RR 1.78, 95% CI 0.38 to 8.36), ‘haemorrhage requiring transfusion or ≥500 mL blood loss’ (RR 0.11, 95% CI 0.01 to 2.03) and ‘incomplete abortion with the need for surgical intervention’ (RR 1.30, 95% CI 0.76 to 2.25) between the interventions. Individual study results showed no difference in patient satisfaction, or ‘need for repeat misoprostol’, although ‘time to onset of bleeding or cramping’ was longer after simultaneous than interval administration. The quality of evidence was very low to moderate.Conclusion: The published data support the use of simultaneous mifepristone and misoprostol for medical abortion up to 9+0weeks in women who prefer this method of administration.
- 20 January 2020
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 47 (2) , 84-89
Anti-D prophylaxis for rhesus D (RhD)-negative women having an abortion of a pregnancy up to 13+6weeks’ gestation: a systematic review and new NICE consensus guidelines
Background: In order to develop the 2019 National Institute for Health and Care Excellence (NICE) national guideline on abortion care for the National Health Service1we undertook a systematic review comparing anti-D prophylaxis to no prophylaxis in rhesus D (RhD)-negative women undergoing medical or surgical abortion of pregnancy at ≤13+6weeks’ gestationMethods: We searched Embase, Medline and the Cochrane Library on 19 October 2018. We also consulted experts and checked reference lists for any missed trials. Eligible studies were randomised controlled trials and non-randomised comparative studies, published in English from 1985 onwards, comparing anti-D prophylaxis to no anti-D prophylaxis in RhD-negative women undergoing medical or surgical abortion at ≤13+6weeks’ gestation, and reporting subsequent anti-D isoimmunisation/sensitisation or subsequent affected pregnancy. These outcomes were to be analysed as risk ratios in Review Manager 5.3 using the Mantel-Haenszel statistical method and a fixed or random effect model. The overall quality of the evidence was planned to be assessed using GRADE.Results: The search identified 426 potentially relevant studies of which none met the inclusion criteria. Recommendations for practice were therefore based on the clinical expertise of the guideline committee.Conclusions: (1) Offer anti-D prophylaxis to women who are Rhesus D negative who are having an abortion after 10+0weeks’ gestation. (2) Do not offer anti-D prophylaxis to women who are having a medical abortion up to and including 10+0weeks’ gestation. (3) Consider anti-D prophylaxis for women who are rhesus D negative and are having a surgical abortion up to and including 10+0weeks’ gestation.
- 20 January 2020
- Published by BMJ in BMJ Sexual & Reproductive Health
- Vol. 47 (2) , 84-89
Anti-D prophylaxis for rhesus D (RhD)-negative women having an abortion of a pregnancy up to 13+6weeks’ gestation: a systematic review and new NICE consensus guidelines
Background: In order to develop the 2019 National Institute for Health and Care Excellence (NICE) national guideline on abortion care for the National Health Service1we undertook a systematic review comparing anti-D prophylaxis to no prophylaxis in rhesus D (RhD)-negative women undergoing medical or surgical abortion of pregnancy at ≤13+6weeks’ gestationMethods: We searched Embase, Medline and the Cochrane Library on 19 October 2018. We also consulted experts and checked reference lists for any missed trials. Eligible studies were randomised controlled trials and non-randomised comparative studies, published in English from 1985 onwards, comparing anti-D prophylaxis to no anti-D prophylaxis in RhD-negative women undergoing medical or surgical abortion at ≤13+6weeks’ gestation, and reporting subsequent anti-D isoimmunisation/sensitisation or subsequent affected pregnancy. These outcomes were to be analysed as risk ratios in Review Manager 5.3 using the Mantel-Haenszel statistical method and a fixed or random effect model. The overall quality of the evidence was planned to be assessed using GRADE.Results: The search identified 426 potentially relevant studies of which none met the inclusion criteria. Recommendations for practice were therefore based on the clinical expertise of the guideline committee.Conclusions: (1) Offer anti-D prophylaxis to women who are Rhesus D negative who are having an abortion after 10+0weeks’ gestation. (2) Do not offer anti-D prophylaxis to women who are having a medical abortion up to and including 10+0weeks’ gestation. (3) Consider anti-D prophylaxis for women who are rhesus D negative and are having a surgical abortion up to and including 10+0weeks’ gestation.
- 28 December 2019
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (4) , 451-458
Initiation of abortion before there is definitive ultrasound evidence of intrauterine pregnancy: A systematic review with meta‐analyses
Introduction: Women are increasingly presenting for abortion at very early gestation. However, providers may be reluctant to conduct abortion at this stage as they may be concerned that they cannot exclude an ectopic pregnancy or that they may terminate a non‐viable pregnancy, or may be concerned that both medical and surgical methods may be less effective at this stage of gestation. This provider concern may result in delays in the abortion as additional investigations may be required until an intrauterine pregnancy can be confirmed. Additional unnecessary visits may be distressing for women and waste health service resources. The objective of this systematic review was to determine whether it is safe and effective to initiate abortion before there is ultrasound evidence of an intrauterine pregnancy.Material and methods: We searched Embase Classic, Embase; Ovid MEDLINE® Epub Ahead‐of‐Print, In‐Process & Other Non‐Indexed Citations, Ovid MEDLINE® Daily, Ovid MEDLINE®; and Cochrane Library on 25 October 2019. Eligible studies were randomized and non‐randomized comparative studies, published in English from 1985, comparing initiation of abortion before there is definitive evidence of an intrauterine pregnancy with initiation afterwards. We assessed risk‐of‐bias using the Newcastle‐Ottowa scale. All outcomes were analyzed as risk ratios (RR) and meta‐analyzed using the Mantel‐Haenszel method. The quality of the evidence was assessed using GRADE.Results: Two non‐randomized studies (n = 3785) showed no differences in “missed ectopic pregnancy” (RR = 0.26, 95% CI 0.03‐2.12), “ongoing pregnancy” (RR = 1.06, 95% CI 0.34‐3.34), or “complete abortion without surgical intervention” (RR = 1, 95% CI 0.98‐1.02) between initiation of medical abortion before or after ultrasound evidence of an intrauterine pregnancy. A third non‐randomized study (n = 1530) showed no differences between initiation of surgical abortion before or after ultrasound evidence of an intrauterine pregnancy in “missed ectopic pregnancy” (no events), “ongoing pregnancy” (RR = 0.56, 95% CI 0.03‐11.59) or “complete abortion without repeat surgical intervention” (RR = 1, 95% CI 0.99‐1.01). The quality of evidence was very low.Conclusions: Initiation of abortion before there is definitive ultrasound evidence of an intrauterine pregnancy in women without signs or symptoms of an ectopic pregnancy should be considered.
- 28 December 2019
- Published by Wiley in Acta Obstetricia et Gynecologica Scandinavica
- Vol. 99 (4) , 451-458
Initiation of abortion before there is definitive ultrasound evidence of intrauterine pregnancy: A systematic review with meta‐analyses
Introduction: Women are increasingly presenting for abortion at very early gestation. However, providers may be reluctant to conduct abortion at this stage as they may be concerned that they cannot exclude an ectopic pregnancy or that they may terminate a non‐viable pregnancy, or may be concerned that both medical and surgical methods may be less effective at this stage of gestation. This provider concern may result in delays in the abortion as additional investigations may be required until an intrauterine pregnancy can be confirmed. Additional unnecessary visits may be distressing for women and waste health service resources. The objective of this systematic review was to determine whether it is safe and effective to initiate abortion before there is ultrasound evidence of an intrauterine pregnancy.Material and methods: We searched Embase Classic, Embase; Ovid MEDLINE® Epub Ahead‐of‐Print, In‐Process & Other Non‐Indexed Citations, Ovid MEDLINE® Daily, Ovid MEDLINE®; and Cochrane Library on 25 October 2019. Eligible studies were randomized and non‐randomized comparative studies, published in English from 1985, comparing initiation of abortion before there is definitive evidence of an intrauterine pregnancy with initiation afterwards. We assessed risk‐of‐bias using the Newcastle‐Ottowa scale. All outcomes were analyzed as risk ratios (RR) and meta‐analyzed using the Mantel‐Haenszel method. The quality of the evidence was assessed using GRADE.Results: Two non‐randomized studies (n = 3785) showed no differences in “missed ectopic pregnancy” (RR = 0.26, 95% CI 0.03‐2.12), “ongoing pregnancy” (RR = 1.06, 95% CI 0.34‐3.34), or “complete abortion without surgical intervention” (RR = 1, 95% CI 0.98‐1.02) between initiation of medical abortion before or after ultrasound evidence of an intrauterine pregnancy. A third non‐randomized study (n = 1530) showed no differences between initiation of surgical abortion before or after ultrasound evidence of an intrauterine pregnancy in “missed ectopic pregnancy” (no events), “ongoing pregnancy” (RR = 0.56, 95% CI 0.03‐11.59) or “complete abortion without repeat surgical intervention” (RR = 1, 95% CI 0.99‐1.01). The quality of evidence was very low.Conclusions: Initiation of abortion before there is definitive ultrasound evidence of an intrauterine pregnancy in women without signs or symptoms of an ectopic pregnancy should be considered.
- 9 February 2017
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (10) , 2403-2418
Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review
We examined the additional prognostic value for survival of cell-of-origin, and MYC, BCL2 and BCL6 translocation status to that provided by the International Prognostic Index in newly-diagnosed diffuse large B-cell lymphoma (DLBCL) patients treated firstline with rituximab-containing immunochemotherapy. We searched Medline, Premedline, Embase, the Cochrane Library, Web of Science, and ISI Proceedings (2000–2015) and assessed study risk-of-bias using a prognostic study checklist. Forty-four studies of moderate–high risk of bias with 100–712 participants were included. Immunohistochemistry-determined cell-of-origin, and BCL2 and BCL6 translocation status added no additional prognostic value. Half of the studies on gene expression profiling-determined cell-of-origin and MYC translocation status found that germinal center B-cell–like (GCB) and no translocation were associated with better overall survival (OS) whereas the remaining studies found no effect of these covariates. Further studies are required to ensure that biological information assessed using newer technologies can be reliably used for studies that incorporate newer agents targeting distinct molecular abnormalities identified in high-risk DLBCL patients.
- 9 February 2017
- Published by Taylor & Francis in Leukemia & Lymphoma
- Vol. 58 (10) , 2403-2418
Does cell-of-origin or MYC, BCL2 or BCL6 translocation status provide prognostic information beyond the International Prognostic Index score in patients with diffuse large B-cell lymphoma treated with rituximab and chemotherapy? A systematic review
We examined the additional prognostic value for survival of cell-of-origin, and MYC, BCL2 and BCL6 translocation status to that provided by the International Prognostic Index in newly-diagnosed diffuse large B-cell lymphoma (DLBCL) patients treated firstline with rituximab-containing immunochemotherapy. We searched Medline, Premedline, Embase, the Cochrane Library, Web of Science, and ISI Proceedings (2000–2015) and assessed study risk-of-bias using a prognostic study checklist. Forty-four studies of moderate–high risk of bias with 100–712 participants were included. Immunohistochemistry-determined cell-of-origin, and BCL2 and BCL6 translocation status added no additional prognostic value. Half of the studies on gene expression profiling-determined cell-of-origin and MYC translocation status found that germinal center B-cell–like (GCB) and no translocation were associated with better overall survival (OS) whereas the remaining studies found no effect of these covariates. Further studies are required to ensure that biological information assessed using newer technologies can be reliably used for studies that incorporate newer agents targeting distinct molecular abnormalities identified in high-risk DLBCL patients.